Human C-Reactive Protein/CRP QuicKit ELISA

CRP is spiked at three known concentrations throughout the range of the assay and run to measure response of the spiked sample matrix. Culture media recovery is 95% compared to 84% for the top competitor. In spike and recovery experiments, natural samples are spiked with the recombinant target analyte of interest to identify interference caused by sample matrices.

• Reactivity: Hu
• Applications: ELISA
• Conjugate: HRP

Human C-Reactive Protein/CRP QuicKit ELISA Summary

• Background: The Quantikine^® QuicKit™ Human C-Reactive Protein/CRP Immunoassay is a one step, 80-minute solid phase ELISA designed to measure human CRP levels in cell culture supernates, serum, and plasma. It contains NS0-expressed recombinant human CRP and antibodies raised against the recombinant protein. Results obtained using natural human CRP showed linear curves that were parallel to ...the standard curves obtained using the QuicKit™ standards. These results indicate that this kit can be used to determine relative mass values for natural human CRP.
  Show More
• Specificity: Natural and recombinant human CRP.
• Source: N/A
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human C-Reactive Protein/CRP QuicKit ELISA

• C-Reactive Protein
• C-reactive protein, pentraxin-related
• CRP
• MGC88244
• pentraxin 1
• PTX1MGC149895

Background

C-Reactive Protein (CRP), also known as Pentraxin 1, is a non-glycosylated protein in the Pentraxin family that also includes Pentraxin 2/SAP and Pentraxin 3/TSG-14. CRP functions as a sensor and activator of the innate immune response (1). In humans, it is a major acute-phase protein; its circulating concentration is dramatically elevated at the onset of inflammation (2). In mice, however, serum CRP levels increase only slightly during inflammation, and the analogous acute phase role is filled by Pentraxin 2 (3). CRP assembles non-covalently into a 110-120 kDa cyclical pentamer (4). Mature human CRP shares 71% and 64% amino acid (aa) sequence identity with mouse and rat CRP, respectively (5). 

CRP binds and opsonizes apoptotic cells (6-8) as well as bacteria such as S. pneumoniae (9, 10). It subsequently enhances the phagocytosis of these opsonized cells (6, 8-10). CRP additionally binds several proteins in the complement cascade including C1q, C4BP, and Factor H (8, 11-13). It enhances activation of the classical complement pathway and the deposition of C3b (9). In later stages of the response, CRP inhibits complement-mediated cell lysis through its binding to C4BP and Factor H (8, 12). These interactions induce the upregulation of complement inhibitory proteins CD46, CD59, and CD55/DAF and inhibit assembly of the membrane attack complex (MAC) (8, 14). 

CRP binds to Fc gamma RI, Fc gamma RIIA, and Fc gamma RIIB on macrophages and dendritic cells (15-17), and Fc receptors are required for the phagocytosis of CRP-opsonized target cells (6, 10, 18). CRP binding to Fc gamma RI induces Src activation which subsequently triggers the inhibitory Fc gamma RIIb and dampens the inflammatory response (15, 19). CRP additionally promotes dendritic cell maturation and humoral immunity (10). In cardiovascular disease, CRP binds to oxidized LDL, exacerbates tissue damage in coronary artery infarction, and inhibits the repair of injured vascular endothelium (7, 19, 20). 

Publications for C-Reactive Protein/CRP (QK1707)(1)

Publication using QK1707

• Warren, KJ;Beck, EM;Callahan, SJ;Helms, MN;Middleton, E;Maddock, S;Carr, JR;Harris, D;Blagev, DP;Lanspa, MJ;Brown, SM;Paine, R; Alveolar macrophages from EVALI patients and e-cigarette users: a story of shifting phenotype Respiratory research 2023-06-17 [PMID: 37330506] (Human)